Metabolomics in multiple sclerosis

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple sclerosis (MS) is a chronic demyelinating disorder of the central nervous system with inflammatory and degenerative components. The cause of MS remains unknown although genetic and environmental factors appear to play a role in its etiopathogenesis. Metabolomics is a new €omics€ technology that aims at measuring small molecules in various biological matrices and can provide information that is not readily obtained from genomics, transcriptomics, or proteomics. Currently, several different analytical platforms exist for metabolomics, and both untargeted and targeted approaches are being employed. Methods of analysis of metabolomics data are also being developed and no consensus currently exists on the optimal approach to analysis and interpretation of these data. Metabolomics has the potential to provide putative biomarkers, insights into the pathophysiology of the disease, and to aid in precision medicine for patients with MS.

Original languageEnglish (US)
Pages (from-to)451-460
Number of pages10
JournalMultiple Sclerosis
Volume22
Issue number4
DOIs
StatePublished - Apr 1 2016

Keywords

  • biomarkers
  • mass spectrometry
  • Metabolomics
  • multiple sclerosis
  • nuclear magnetic resonance

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Metabolomics in multiple sclerosis'. Together they form a unique fingerprint.

Cite this